Reacción a "Despite weight loss, most obesity medications do not significantly improve quality of life, according to a study"

This is a comprehensive and methodologically sound review, involving nearly 100,000 participants, and it has the merit of evaluating these treatments not only based on weight loss but also on their effects on quality of life, cardiovascular events, muscle mass, and adverse effects. Its main conclusion is reasonable: losing more weight does not automatically mean a better quality of life or an immediate reduction in cardiovascular risk.

However, the results must be interpreted with caution. Most of the trials were relatively short and were not designed to detect heart attacks, mortality, or kidney disease. These benefits require years of follow-up and are primarily seen in patients who already have a high cardiovascular risk. Therefore, the study does not prove that these drugs lack cardiovascular benefits, but rather that for many of them, we do not yet have sufficient evidence. Furthermore, cardiovascular risk depends not only on weight loss but also on age, pre-existing conditions, improvements in glucose levels, blood pressure, and lipid profiles, and possibly on the specific effects of each medication.

The absence of a large average improvement in quality of life may also be explained by the fact that very different scales were combined and that adverse effects, fatigue, or loss of muscle mass may offset part of the perceived benefit. Comparisons between medications are, moreover, mostly indirect, and no individual data are available to determine which patients benefit the most. This is a very useful study for guiding shared decision-making, but it does not yet allow us to identify an absolute winner or rule out long-term benefits.

[Regarding the editorial accompanying the study in the same journal]

The editorial provides an appropriate context for the study and is correct in emphasizing that treatment must be individualized, taking into account not only weight loss but also comorbidities, adverse effects, adherence, cost, and patient preferences. However, it is an editorial opinion piece, not new research, and it is somewhat optimistic regarding the possibility of choosing the ideal medication: the meta-analysis itself lacks individual-level data, and a significant portion of the comparisons is based on indirect evidence. Its strongest message is that not all patients need the same treatment and that long-term studies with clinically relevant outcomes are still lacking.